




The relative strengths and weaknesses of Esperion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 4.2% points. The greatest weakness of Esperion Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 156% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	328,972
Cost of Goods Sold	0
Intangible Assets	56
Liabilities, Current	73,352
Liabilities, Non-Current	1,158
Other Assets	51,898
Other Compr. Net Income	-31
Other Expenses	60,570
Other Liabilities	504,024
Other Net Income	3,975
Other Revenues	78,447
Property and Equipment	664
Research and Development	105,975
Selling, General and Administrative Expense	184,985

Output Variable	Value in 1000 USD
Assets	381,590
Liabilities	578,534
Expenses	351,530
Revenues	78,447
Stockholders Equity	-196,944
Net Income	-269,108
Comprehensive Net Income	-269,124
BaseVar	697,054
ECR before LimitedLiability	-145%
Economic Capital Ratio	119%